Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
26 Apr 24
424B3
Prospectus supplement
23 Apr 24
EFFECT
Notice of effectiveness
22 Apr 24
424B5
Prospectus supplement for primary offering
18 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Apr 24
8-K
Departure of Directors or Certain Officers
16 Apr 24
S-3
Shelf registration
12 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
D
$287.50 k in equity / options / securities to be acquired, sold $287.50 k, 1 investor
14 Mar 24
8-K
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
6 Mar 24
424B5
Prospectus supplement for primary offering
25 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
UPLOAD
Letter from SEC
19 Jan 24
8-K
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
18 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
16 Jan 24
S-3
Shelf registration
12 Jan 24
DEFA14A
Additional proxy soliciting materials
14 Dec 23
S-8
Registration of securities for employees
12 Dec 23
DEF 14A
Definitive proxy
8 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Nov 23
PRE 14A
Preliminary proxy
24 Nov 23
424B3
Prospectus supplement
20 Nov 23
EFFECT
Notice of effectiveness
20 Nov 23
CORRESP
Correspondence with SEC
15 Nov 23
8-K
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
UPLOAD
Letter from SEC
14 Nov 23
S-1
IPO registration
8 Nov 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
8-K/A
Completion of Acquisition or Disposition of Assets
30 Oct 23
NT 10-Q/A
Notice of late quarterly filing (amended)
30 Oct 23
D
$4.00 mm in equity / options / securities to be acquired, sold $4.00 mm, 1 investor
26 Oct 23
8-K
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
24 Oct 23
ARS
2022 FY
Annual report to shareholders
2 Oct 23
DEF 14A
Definitive proxy
29 Sep 23
8-K
Other Events
26 Sep 23
8-K
Entry into a Material Definitive Agreement
21 Sep 23
Latest ownership filings
4
Robertson H. Gilliland
27 Mar 24
4
James W. Jr. Newman
27 Mar 24
4
Joseph Truluck
27 Mar 24
4
Cary J Claiborne
27 Mar 24
4
J. Kermit Anderson
27 Mar 24
4
Kevin Schuyler
27 Mar 24
4
Tony Goodman
27 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Kevin Schuyler
3 Oct 23
4
Bankole A. Johnson
2 Jun 23
4
Joseph Truluck
25 May 23
4
William B. Stilley III
25 May 23
4
Kevin Schuyler
25 May 23
4
James W. Jr. Newman
25 May 23
4
Tony Goodman
25 May 23
4
Robertson H. Gilliland
25 May 23
4
Cary J Claiborne
25 May 23
4
J. Kermit Anderson
25 May 23
4
William B. Stilley III
3 Jan 23
4
Cary J Claiborne
20 Sep 22
4
William B. Stilley III
23 Aug 22
4
Cary J Claiborne
22 Aug 22
4
Tony Goodman
28 Jun 22
4
Bankole A. Johnson
25 Feb 22
4
Tony Goodman
25 Feb 22
4
Joseph Truluck
25 Feb 22
4
William B. Stilley III
25 Feb 22
4
Kevin Schuyler
25 Feb 22
4
James W. Jr. Newman
25 Feb 22
4
Robertson H. Gilliland
25 Feb 22
4
Cary J Claiborne
25 Feb 22
4
J. Kermit Anderson
25 Feb 22
SC 13D/A
Schuyler Kevin
18 Feb 22
SC 13G/A
Peikin Mark Howard
14 Feb 22
4
James W. Jr. Newman
3 Jan 22
4
Kevin Schuyler
23 Dec 21
4
Cary J Claiborne
8 Dec 21
4
William B. Stilley III
1 Dec 21
4
James W. Jr. Newman
30 Nov 21
4
Cary J Claiborne
3 Nov 21